An Open Label, Multicenter Phase I Study To Evaluate Safety and Efficacy of P276-00 [P 276] in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma.

Trial Profile

An Open Label, Multicenter Phase I Study To Evaluate Safety and Efficacy of P276-00 [P 276] in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 26 Jan 2013

At a glance

  • Drugs P 276 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Piramal Phytocare
  • Most Recent Events

    • 01 May 2009 Piramal Life Sciences Limited added as sponser and affiliate as reported by ClinicalTrials.gov.
    • 01 May 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 16 Dec 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top